JP2022537987A5 - - Google Patents

Info

Publication number
JP2022537987A5
JP2022537987A5 JP2021574936A JP2021574936A JP2022537987A5 JP 2022537987 A5 JP2022537987 A5 JP 2022537987A5 JP 2021574936 A JP2021574936 A JP 2021574936A JP 2021574936 A JP2021574936 A JP 2021574936A JP 2022537987 A5 JP2022537987 A5 JP 2022537987A5
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
nucleotide sequence
double
stranded
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021574936A
Other languages
English (en)
Japanese (ja)
Other versions
JP7463410B2 (ja
JP2022537987A (ja
Filing date
Publication date
Priority claimed from GBGB1909500.9A external-priority patent/GB201909500D0/en
Priority claimed from GBGB1910526.1A external-priority patent/GB201910526D0/en
Priority claimed from GBGB2000906.4A external-priority patent/GB202000906D0/en
Application filed filed Critical
Priority claimed from PCT/GB2020/051573 external-priority patent/WO2021001646A2/en
Publication of JP2022537987A publication Critical patent/JP2022537987A/ja
Publication of JP2022537987A5 publication Critical patent/JP2022537987A5/ja
Application granted granted Critical
Publication of JP7463410B2 publication Critical patent/JP7463410B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021574936A 2019-07-02 2020-06-30 アポリポタンパク質bアンタゴニスト Active JP7463410B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1909500.9A GB201909500D0 (en) 2019-07-02 2019-07-02 Antagonist
GB1909500.9 2019-07-02
GB1910526.1 2019-07-23
GBGB1910526.1A GB201910526D0 (en) 2019-07-23 2019-07-23 Antagonist
GB2000906.4 2020-01-22
GBGB2000906.4A GB202000906D0 (en) 2020-01-22 2020-01-22 Antagonist
PCT/GB2020/051573 WO2021001646A2 (en) 2019-07-02 2020-06-30 Apolipoprotein b antagonist

Publications (3)

Publication Number Publication Date
JP2022537987A JP2022537987A (ja) 2022-08-31
JP2022537987A5 true JP2022537987A5 (https=) 2023-07-07
JP7463410B2 JP7463410B2 (ja) 2024-04-08

Family

ID=71949646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021574936A Active JP7463410B2 (ja) 2019-07-02 2020-06-30 アポリポタンパク質bアンタゴニスト

Country Status (7)

Country Link
US (1) US20230027604A1 (https=)
EP (1) EP3965781A2 (https=)
JP (1) JP7463410B2 (https=)
CN (1) CN114072503A (https=)
CA (1) CA3143404C (https=)
GB (1) GB2585278B (https=)
WO (1) WO2021001646A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202020534D0 (en) * 2020-12-23 2021-02-03 Argonaute Rna Ltd Conjugate
US20250304966A1 (en) * 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023041508A2 (en) * 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
GB2618915B (en) * 2022-05-18 2024-08-14 Argonaute Rna Ltd Treatment of cardiovascular disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377873B1 (en) * 2004-09-24 2014-08-20 Alnylam Pharmaceuticals, Inc. RNAi modulation of ApoB and uses thereof
EP1891216B1 (en) * 2005-05-25 2012-02-22 The University Of York Hybrid interfering rna
EP2105145A1 (en) * 2008-03-27 2009-09-30 ETH Zürich Method for muscle-specific delivery lipid-conjugated oligonucleotides
EP2449106B1 (en) * 2009-07-01 2015-04-08 Protiva Biotherapeutics Inc. Compositions and methods for silencing apolipoprotein b
US20150025122A1 (en) * 2009-10-12 2015-01-22 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
AU2021295358B2 (en) * 2020-06-24 2026-01-22 Sapreme Technologies B.V. Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate
US20250304966A1 (en) * 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease

Similar Documents

Publication Publication Date Title
JP2023519140A5 (https=)
JP2022537987A5 (https=)
JP2024531728A5 (https=)
Nielsen Peptide nucleic acid. A molecule with two identities
Wen et al. Selection of genomic sequences that bind tightly to Ff gene 5 protein: primer-free genomic SELEX
JP2024500036A5 (https=)
JP2017079759A5 (https=)
JP2010533171A5 (https=)
WO2023041508A3 (en) Treatment of cardiovascular disease
JP2010512747A5 (https=)
JP2001512034A (ja) 最大の自己アセンブリを行う樹枝状核酸
JP2005517433A5 (https=)
JP2020518552A5 (https=)
JP2006500958A5 (https=)
JP2021167329A5 (https=)
Imbert et al. Lowering mutant huntingtin using tricyclo-DNA antisense oligonucleotides as a therapeutic approach for Huntington's disease
JP2003503355A5 (https=)
JP2005517412A5 (https=)
JP2024538859A5 (https=)
CN103443277A (zh) 淀粉样蛋白低聚物结合核酸适体
JPWO2021187392A5 (https=)
NO930513D0 (no) Oligonukleotid modulering av celleadhesjon
JP2006521824A5 (https=)
JP2009523006A5 (https=)
JP2007517498A5 (https=)